Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/2159-8290.CD-16-0716 http://scihub22266oqcxt.onion/10.1158/2159-8290.CD-16-0716 C5293166!5293166!27655435     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Discov 2016 ; 6 (10): 1090-105 Nephropedia Template TP {{tp|p=27655435|t=2016. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy |pdf=|usr=}}{{27655435}} gab.com Text Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy JO: Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=27655435 #FOAvip The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with the cancer cells? ability to respond to stromal signals, as illustrated by the approved PI3K? inhibitor Idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3K? or PI3K? may unleash more potent anti-tumor T-cell responses, by inhibiting regulatory T-cells and immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K inhibitors to enhance cancer therapy. Future work should therefore focus on the effects of PI3K inhibitors on the stroma, in addition to their direct effects on tumors.Significance: The PI3K pathway extends beyond the direct regulation of cancer cell proliferation and survival. In B-cell malignancies, targeting PI3K purges the tumor cells from their protective microenvironment. Moreover, we propose that PI3K isoform-selective inhibitors may be exploited in the context of cancer immunotherapy and by targeting angiogenesis to improve drug and immune cell delivery. Twit Text FOAVip Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy ????Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=27655435 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27655435 #FOAvip English Wikipedia <ref>{{Cite pmid|27655435}}</ref> Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy #MMPMID27655435 Okkenhaug K; Graupera M; Vanhaesebroeck B Cancer Discov 2016[Oct]; 6 (10): 1090-105 PMID27655435show ga The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with the cancer cells? ability to respond to stromal signals, as illustrated by the approved PI3K? inhibitor Idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3K? or PI3K? may unleash more potent anti-tumor T-cell responses, by inhibiting regulatory T-cells and immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K inhibitors to enhance cancer therapy. Future work should therefore focus on the effects of PI3K inhibitors on the stroma, in addition to their direct effects on tumors.Significance: The PI3K pathway extends beyond the direct regulation of cancer cell proliferation and survival. In B-cell malignancies, targeting PI3K purges the tumor cells from their protective microenvironment. Moreover, we propose that PI3K isoform-selective inhibitors may be exploited in the context of cancer immunotherapy and by targeting angiogenesis to improve drug and immune cell delivery. äTargeting PI3K in cancer: impact on tumor cells, their protective stro(epmc).pdf DeepDyve Pubget Overpricing